Co-Authors
This is a "connection" page, showing publications co-authored by SUSAN HILSENBECK and SUZANNE FUQUA.
Connection Strength
1.748
-
Genomic approaches to understanding and treating breast cancer. Breast Dis. 2004; 19:35-46.
Score: 0.237
-
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance. J Natl Cancer Inst. 1999 Mar 03; 91(5):453-9.
Score: 0.170
-
Metastasis tumor-associated protein 2 enhances metastatic behavior and is associated with poor outcomes in estrogen receptor-negative breast cancer. Breast Cancer Res Treat. 2013 Oct; 141(3):375-384.
Score: 0.116
-
Pharmacogenetics of breast cancer: toward the individualization of therapy. Cancer Invest. 2009 Aug; 27(7):699-703.
Score: 0.087
-
Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer. Clin Cancer Res. 2007 Jun 01; 13(11):3235-43.
Score: 0.075
-
Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance. Cancer Res. 2006 Jun 01; 66(11):5950-9.
Score: 0.070
-
The promise of microarrays in the management and treatment of breast cancer. Breast Cancer Res. 2005; 7(3):100-4.
Score: 0.065
-
Genomic approaches in the management and treatment of breast cancer. Br J Cancer. 2005 Feb 28; 92(4):618-24.
Score: 0.064
-
PKMYT1 is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 May 23.
Score: 0.061
-
Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res. 2004 Apr 15; 10(8):2751-60.
Score: 0.060
-
Sp1 is essential for estrogen receptor alpha gene transcription. J Steroid Biochem Mol Biol. 2002 Sep; 82(1):7-18.
Score: 0.054
-
Correction to: Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2022 Jan; 41(3):460.
Score: 0.052
-
Hsp27-induced MMP-9 expression is influenced by the Src tyrosine protein kinase yes. Biochem Biophys Res Commun. 2001 Mar 23; 282(1):186-93.
Score: 0.049
-
Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.
Score: 0.048
-
A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 2000 Aug 01; 60(15):4026-9.
Score: 0.047
-
Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Res Treat. 1999 Jul; 56(2):187-96.
Score: 0.043
-
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer. Ann Oncol. 2019 06 01; 30(6):927-933.
Score: 0.043
-
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer. Breast Cancer Res Treat. 2018 02; 167(3):731-740.
Score: 0.039
-
The small heat shock protein hsp27 increases invasiveness but decreases motility of breast cancer cells. Invasion Metastasis. 1997; 17(3):113-23.
Score: 0.037
-
Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Res Treat. 2016 08; 158(3):441-54.
Score: 0.035
-
The small heat shock protein HSP27 is not an independent prognostic marker in axillary lymph node-negative breast cancer patients. Clin Cancer Res. 1996 Jul; 2(7):1199-206.
Score: 0.035
-
Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. Cancer Res. 2016 04 01; 76(7):1942-53.
Score: 0.034
-
Relationship of clone 4 estrogen receptor variant messenger RNA expression to some known prognostic variables in human breast cancer. Clin Cancer Res. 1995 Feb; 1(2):155-9.
Score: 0.032
-
Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015 Apr 01; 21(7):1688-98.
Score: 0.031
-
Heat shock proteins and drug resistance. Breast Cancer Res Treat. 1994; 32(1):67-71.
Score: 0.030
-
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer. Breast Cancer Res Treat. 2011 Oct; 129(3):819-27.
Score: 0.025
-
Loss of Rho GDIa and resistance to tamoxifen via effects on estrogen receptor a. J Natl Cancer Inst. 2011 Apr 06; 103(7):538-52.
Score: 0.024
-
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May; 121(1):1-11.
Score: 0.022
-
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst. 2003 Mar 05; 95(5):353-61.
Score: 0.014
-
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J Natl Cancer Inst. 2000 Dec 06; 92(23):1926-34.
Score: 0.012
-
Loss of heterozygosity at D14S62 and metastatic potential of breast cancer. J Natl Cancer Inst. 1999 Aug 18; 91(16):1391-7.
Score: 0.011
-
Multiple splicing variants of the estrogen receptor are present in individual human breast tumors. J Steroid Biochem Mol Biol. 1996 Nov; 59(3-4):251-60.
Score: 0.009
-
Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol. 1995 Oct; 147(4):905-11.
Score: 0.008
-
Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol. 1994 Mar; 12(3):467-74.
Score: 0.007